Lee Johnson Capital Management LLC Has $849,000 Holdings in Gilead Sciences, Inc. $GILD

Lee Johnson Capital Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 72.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,093 shares of the biopharmaceutical company’s stock after selling 15,729 shares during the quarter. Lee Johnson Capital Management LLC’s holdings in Gilead Sciences were worth $849,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $26,000. Wealth Preservation Advisors LLC grew its holdings in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $28,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Daiwa Securities Group decreased their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Citigroup increased their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. The Goldman Sachs Group raised their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Finally, Rothschild & Co Redburn cut their target price on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $123.76 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm’s 50-day simple moving average is $131.66 and its 200 day simple moving average is $134.28. The stock has a market cap of $153.66 billion, a PE ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 68,000 shares of company stock valued at $8,930,150. 0.30% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.